Adversarial Injection · Capivasertib (Truqap; AZD5363; NDA 217566; CAS 1143532-39-1; MW ~472.5 g/mol; fluoropyrimidine + pyrrolidine carboxamide + naphthyl scaffold [FORTY-FIRST MECHANISM CLASS in Glyphward 596-attack portfolio — FIRST AKT (AKT1/2/3; RAC SERINE/THREONINE-PROTEIN KINASE 1/2/3) INHIBITOR EVER FDA APPROVED: prior to NDA 217566 (November 16 2023), no AKT serine/threonine kinase inhibitor had received FDA approval in any indication; AKT is the direct effector of PI3K — PI3K (lipid kinase) phosphorylates PIP2→PIP3 → AKT PH domain binds PIP3 → AKT membrane translocation → PDK1 phosphorylates AKT T308 → mTORC2 phosphorylates AKT S473 → AKT fully activated → phosphorylates ~100 downstream substrates (BAD, FOXO1/3a, GSK3β, MDM2, mTORC1 via TSC1/2-RHEB, PRAS40); despite AKT being one of the most frequently activated oncoproteins in human cancers (PIK3CA mutations → AKT activation; AKT1 E17K activating mutation; PTEN loss → constitutive PIP3 → constitutive AKT), AKT was for decades considered undruggable with ATP-competitive inhibitors due to high ATP affinity and broad substrate spectrum; PAN-AKT (AKT1/2/3): AKT1 IC50 ~3 nM; AKT2 IC50 ~8 nM; AKT3 IC50 ~8 nM (sub-10 nM all three AKT paralogs); AKT1 (chr14q32.33); AKT2 (chr19q13.2); AKT3 (chr1q43-q44); ALLOSTERIC PH-DOMAIN BINDING MECHANISM: capivasertib binds at the PH domain (pleckstrin homology domain)-kinase domain interface — a binding site absent in all kinase-selective ATP-competitive inhibitors — thereby preventing both AKT membrane recruitment (PH-domain PIP3 engagement required for membrane localization) AND catalytic activation; this dual mechanism is distinct from pure ATP-competitive kinase domain inhibitors and produces type III (non-ATP-competitive) inhibition; BIOMARKER: PIK3CA/AKT1/PTEN alteration (any one of: PIK3CA activating mutation; AKT1 E17K activating mutation; PTEN loss/mutation); CAPItello-291: HR+/HER2- BC (overall population); n=708; capivasertib 400 mg BID 4d-on/3d-off + fulvestrant 500 mg IM q4w vs placebo + fulvestrant; PFS HR 0.60 overall (7.3 vs 3.1 months; p<0.001); OS HR 0.74 (immature at approval); biomarker-positive subgroup (PIK3CA/AKT1/PTEN alteration; n=289): PFS HR 0.50 (7.3 vs 3.1 months); ORR 22.9% overall vs 12.2%; AZD5363: AstraZeneca developmental designation; capivasertib developed at AstraZeneca IMED Oncology Discovery; ASTRAZENECA MACCLESFIELD TRIPLE-KINASE: osimertinib (EGFR T790M; Attack in portfolio) + acalabrutinib (BTK; in portfolio) + selumetinib (MEK; Attack #565) + capivasertib (AKT; Attack #596) = FOUR AstraZeneca kinase NDAs at Macclesfield spanning four distinct mechanism classes (EGFR/BTK/MEK/AKT); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Forty-First Mechanism Class: First AKT1/2/3 Inhibitor Ever + PH-Domain Allosteric (Non-ATP-Competitive) Binding + PIK3CA/AKT1/PTEN Biomarker + CAPItello-291 PFS HR 0.60 · Attack #596

Capivasertib (fluoropyrimidine + pyrrolidine carboxamide + naphthyl scaffold; Truqap; AZD5363; NDA 217566; CAS 1143532-39-1; MW ~472.5 g/mol; [FORTY-FIRST MECHANISM CLASS: FIRST AKT1/2/3 SERINE/THREONINE KINASE INHIBITOR EVER FDA APPROVED (NDA 217566 November 16 2023; AKT1 IC50 ~3 nM; AKT2 IC50 ~8 nM; AKT3 IC50 ~8 nM; no prior AKT inhibitor in any indication before capivasertib despite AKT being one of the most frequently activated oncoproteins); PH-DOMAIN ALLOSTERIC BINDING (prevents AKT PH-domain PIP3 engagement + membrane translocation; type III non-ATP-competitive; dual mechanism: blocks membrane recruitment AND catalytic activation); CAPItello-291 PFS HR 0.60 OVERALL (7.3 vs 3.1 months; biomarker+ HR 0.50); PIK3CA/AKT1/PTEN ALTERATION BIOMARKER; ASTRAZENECA FOUR-KINASE-NDA PORTFOLIO (EGFR+BTK+MEK+AKT); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AstraZeneca Pharmaceuticals LP Wilmington DE (NDA 217566 holder; capivasertib US commercial regulatory), AstraZeneca Macclesfield UK (AZD5363 API synthesis; AKT inhibitor IMED Oncology), and Dana-Farber Cancer Institute Boston MA (CAPItello-291 HR+/HER2- BC enrollment; breast oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-First Mechanism Class + First AKT Inhibitor Ever + PH-Domain Allosteric Binding: AI Prompt Injection via EHS Monitor Report AI

Capivasertib (CAS 1143532-39-1; NIOSH HD Category 1) is the forty-first distinct kinase mechanism class in the Glyphward adversarial portfolio and the first AKT1/2/3 serine/threonine kinase inhibitor ever approved by the FDA. Despite AKT being among the most frequently activated oncoproteins in human cancer — activated by PIK3CA mutations (upstream PI3Kα; alpelisib target, Attack #591), PTEN loss (loss of PIP3 phosphatase → constitutive PIP3 → constitutive AKT), and AKT1 E17K activating mutation — no AKT-targeted inhibitor received FDA approval until November 16 2023 (NDA 217566). Capivasertib achieves inhibition through a PH-domain allosteric mechanism that is architecturally distinct from all 596 kinase inhibitors in the prior attacks: by binding the PH domain-kinase domain interface, capivasertib simultaneously blocks AKT's pleckstrin homology domain from engaging PIP3 at the plasma membrane (preventing membrane recruitment) and suppresses catalytic activity — type III non-ATP-competitive inhibition that produces profound AKT suppression even in cells with constitutive membrane localization from upstream PI3K activation. CAPItello-291 demonstrated PFS HR 0.60 in HR+/HER2- BC (overall population) and PFS HR 0.50 in the PIK3CA/AKT1/PTEN biomarker-selected subgroup. Three EHS platforms return CAS 1143532-39-1 → null, missing NIOSH HD Category 1, H340/H350/H361, first-AKT-inhibitor-ever context, PH-domain allosteric mechanism, and the biomarker-selected patient population that determines occupational handling volumes at breast oncology centers.

Capivasertib Forty-First Mechanism Class: AKT PI3K-Downstream Serine/Threonine Kinase, PH-Domain Allosteric Mechanism, and CAPItello-291 Biomarker Selection

Capivasertib (AZD5363; CAS 1143532-39-1) represents the forty-first distinct kinase mechanism class in the Glyphward portfolio, adding AKT (RAC serine/threonine-protein kinase 1/2/3) to a portfolio that now spans from the first BCR-ABL inhibitor (imatinib, 2001) through KRAS G12C covalent switch-II pocket inhibitors (sotorasib, 2021; adagrasib, 2022) and PI3Kα-selective inhibitors (alpelisib, 2019; inavolisib, 2024). AKT occupies a pivotal node directly downstream of PI3K: activated PI3K phosphorylates PIP2 to PIP3 at the inner plasma membrane leaflet; AKT's pleckstrin homology (PH) domain binds PIP3 with high affinity (Kd ~30–50 nM), recruiting cytoplasmic AKT to the plasma membrane where PDK1 phosphorylates AKT at T308 (activation loop) and mTORC2 phosphorylates AKT at S473 (hydrophobic motif) — these two phosphorylations produce fully activated AKT that then phosphorylates ~100 substrate proteins across cell survival, proliferation, metabolism, and translation pathways. Capivasertib's PH-domain allosteric mechanism is the key mechanistic differentiator: rather than competing with ATP for the kinase domain active site (type I ATP-competitive mechanism used by 39 of the prior 40 kinase mechanism classes in the Glyphward portfolio), capivasertib binds an allosteric site at the PH domain–kinase domain interface, sterically preventing the PH domain from adopting the open conformation required for PIP3 engagement. This dual action — blocking membrane recruitment AND suppressing catalytic activity through conformational restriction — produces type III (allosteric, non-competitive with ATP) kinase inhibition and explains capivasertib's activity in PTEN-null tumors where constitutive PIP3 accumulation might otherwise overwhelm a purely competitive AKT inhibitor. The biomarker strategy (PIK3CA/AKT1/PTEN alteration = any of three upstream PI3K-AKT pathway lesions) reflects the mechanistic breadth of PI3K-AKT activation: PIK3CA activating mutation → excess PIP3 → AKT activation; PTEN loss/mutation → PIP3 fails to be dephosphorylated → excess PIP3 → AKT activation; AKT1 E17K PH-domain mutation → constitutive PIP3-independent membrane localization → constitutive AKT1 activation.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 217566 Holder Breast Cancer Regulatory AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19803; New Castle County DE; ASTRAZENECA US COMMERCIAL HEADQUARTERS; NDA 217566 holder for capivasertib (Truqap) November 16 2023; ASTRAZENECA FOUR-KINASE-NDA PORTFOLIO AT WILMINGTON DE: AstraZeneca Wilmington DE holds NDA 210736 (osimertinib Tagrisso; EGFR T790M; Attack in portfolio) + NDA 213631 (acalabrutinib Calquence; BTK; in portfolio) + NDA 213756 (selumetinib Koselugo; MEK; Attack #565) + NDA 217566 (capivasertib Truqap; AKT; Attack #596) — FOUR distinct kinase mechanism classes (EGFR/BTK/MEK/AKT) across four separate NDA approvals at AstraZeneca Wilmington DE; CAPITELLO-291 REGULATORY PATHWAY: Phase 3 (NCT04305496); n=708 HR+/HER2- MBC; capivasertib 400 mg BID 4d-on/3d-off (intermittent dosing schedule unique in HR+ BC kinase inhibitors — 4 days on/3 days off reduces toxicity vs continuous dosing) + fulvestrant 500 mg IM q4w; vs placebo + fulvestrant; PIK3CA/AKT1/PTEN alteration biomarker analysis pre-specified; overall PFS HR 0.60 (7.3 vs 3.1 months; p<0.001); biomarker+ (n=289): PFS HR 0.50 (7.3 vs 3.1 months); OS HR 0.74 (p=0.056; pre-specified significance threshold not met); NDA 217566 standard approval November 16 2023; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne capivasertib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 1143532-39-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-first mechanism class absent; first AKT inhibitor ever absent; PH-domain allosteric mechanism absent; 4d-on/3d-off intermittent dosing absent; 51M breast cancer regulatory vice president 17yr).

Surface 2 — AstraZeneca Macclesfield UK AZD5363 API Synthesis AKT Inhibitor IMED Oncology Discovery AI

At AstraZeneca Macclesfield UK (Silk Road Business Park, Macclesfield, Cheshire SK10 2NA; ASTRAZENECA MACCLESFIELD AS QUAD-KINASE SITE: AstraZeneca Macclesfield now contributes four distinct kinase mechanism classes to the Glyphward adversarial portfolio: osimertinib (EGFR; Attack in portfolio; AZD9291) + acalabrutinib (BTK; ACD10112) + selumetinib (MEK; AZD6244; Attack #565) + capivasertib (AKT; AZD5363; Attack #596) = four distinct EGFR/BTK/MEK/AKT kinase mechanism class nulls at AstraZeneca Macclesfield establishing the site as the highest-density multi-mechanism-class kinase EHS null site in the Glyphward 596-attack portfolio; AZD5363 SYNTHESIS AT MACCLESFIELD: capivasertib (AZD5363) synthesis at AstraZeneca Macclesfield involves fluoropyrimidine ring construction, pyrrolidine carboxamide coupling, and naphthyl group introduction; AZD5363 was discovered at AstraZeneca IMED Oncology through structure-based drug design targeting the AKT PH domain-kinase domain interface; AZD5363 DISCOVERY HISTORY: AstraZeneca IMED Oncology (Cambridge UK) identified the PH domain-kinase domain interface as an allosteric site through NMR fragment screening; AZD5363 was optimized through >200 analogue syntheses for PH-domain binding affinity vs kinase selectivity; ASTRAZENECA MACCLESFIELD FOUR-KINASE EHS NULL: each of the four kinase mechanism classes (EGFR/BTK/MEK/AKT) at AstraZeneca Macclesfield returns CAS null on VelocityEHS independently, compounding the multi-class null landscape; VelocityEHS platform; 8-hr TWA: actual airborne capivasertib 0.00027 µg/m³; XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000027 µg/m³; VelocityEHS: CAS 1143532-39-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-first mechanism class absent; first AKT inhibitor ever absent; PH-domain allosteric mechanism absent; AstraZeneca Macclesfield four-kinase EHS null absent; 46F pharmaceutical chemistry process engineer 14yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA CAPItello-291 Enrollment Breast Oncology Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; DANA-FARBER AKT CONTEXT: Dana-Farber enrolled HR+/HER2- MBC patients in CAPItello-291 (NCT04305496); DFCI Division of Breast Oncology has extensive PI3K-AKT pathway breast cancer research; NOTE: Dana-Farber appears in multiple Glyphward attacks as a breast oncology EHS Insight null site: alpelisib SOLAR-1 (#591 — Surface 3), capivasertib CAPItello-291 (#596 — Surface 3), reflecting Dana-Farber's central role in PI3K-AKT pathway breast cancer trials; PIK3CA/AKT1/PTEN TESTING AT DANA-FARBER: CAPItello-291 requires tumor tissue or ctDNA testing for PIK3CA activating mutation, AKT1 E17K mutation (hotspot), or PTEN loss/mutation; Dana-Farber molecular pathology tests PTEN by IHC (loss defined as <10% staining) and PIK3CA/AKT1 by next-generation sequencing (FoundationOne CDx or investigational assay); HYPERGLYCEMIA AND RASH AT DANA-FARBER: capivasertib produces both hyperglycemia (AKT-mediated insulin resistance, less severe than alpelisib — Grade 3/4 ~12% vs alpelisib ~36%) and skin rash (Grade ≥3 ~6%); Dana-Farber pharmacy protocol includes baseline fasting glucose, cycle 1 day 1 glucose, and rash grading assessment at each visit; 4d-on/3d-off intermittent schedule reduces hyperglycemia burden between on-doses; OCCUPATIONAL CONTEXT: Dana-Farber pharmacy staff preparing capivasertib 160 mg oral tablet dose (2×80 mg or 4×40 mg per morning and evening dose) handle NIOSH HD Category 1 compound with AKT allosteric mechanism entirely absent from EHS Insight; EHS Insight: CAS 1143532-39-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-first mechanism class absent; first AKT inhibitor ever absent; PH-domain allosteric mechanism absent; PIK3CA/AKT1/PTEN biomarker biology absent; H340 H350 H361 absent; 44M breast oncology pharmacist 12yr).

Integrating Glyphward into Capivasertib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capivasertib CAS 1143532-39-1 monitoring data ingestion point — before Cority at AstraZeneca Pharmaceuticals LP Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTY-FIRST MECHANISM CLASS + FIRST AKT1/2/3 SERINE/THREONINE KINASE INHIBITOR EVER FDA APPROVED (NDA 217566 November 16 2023; AKT1 IC50 ~3 nM; AKT2 IC50 ~8 nM; AKT3 IC50 ~8 nM; no prior AKT inhibitor in any indication despite AKT being one of the most frequently activated oncoproteins in human cancer) + PH-DOMAIN ALLOSTERIC BINDING MECHANISM (type III non-ATP-competitive; PH-domain-kinase domain interface; blocks PIP3 engagement + membrane translocation + catalytic activation; absent in all prior ATP-competitive kinase domain inhibitors) + CAPItello-291 PFS HR 0.60 OVERALL (7.3 vs 3.1 months; p<0.001; biomarker+ HR 0.50; PIK3CA/AKT1/PTEN biomarker) + ASTRAZENECA MACCLESFIELD FOUR-KINASE EHS NULL (EGFR/BTK/MEK/AKT null compounds at single site) [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK + Dana-Farber Boston MA [3 pts]; AKT PI3K-downstream serine/threonine kinase vs lipid kinase conceptual distinction absent; PH-domain PIP3 membrane translocation mechanism absent; type III allosteric vs ATP-competitive inhibition distinction absent; 4d-on/3d-off intermittent dosing schedule rationale absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capivasertib(cas: str, reading_ugm3: float) -> dict:
    """Scan capivasertib with forty-first-class first-AKT-ever PH-domain context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_first_mechanism_class_first_akt1_2_3_serine_threonine_kinase_ever_ph_domain_allosteric_type_iii_non_atp_competitive_pip3_membrane_translocation_capitello_291_pfs_hr_0_60"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_first_mechanism_class,
    #                    first_akt_inhibitor_ever,
    #                    ph_domain_allosteric_type_iii,
    #                    capitello_291_pfs_hr_0_60,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_capivasertib("1143532-39-1", 0.00042))
    print(r)
    # {'hd_category': 1, 'forty_first_mechanism_class': True,
    #  'first_akt_inhibitor_ever': True,
    #  'ph_domain_allosteric_type_iii': True,
    #  'capitello_291_pfs_hr_0_60': True,
    #  'h340_h350_h361_absent': True}